Sign In
Buy VTRS
$16.39
+0.120 (+0.738%)
At Close: Jul 13, 2026
2 Bruised Dividend Stocks to Buy While They're Cheap
08:15am, Monday, 06'th Jun 2022
Lower share prices won't stop them from hiking their dividends.
Why Shares of Viatris Climbed 18.8% in May
07:56am, Monday, 06'th Jun 2022
The company reported improved net income and free cash flow in the last quarter.
3 Great Dividend Stocks to Buy in June
07:04am, Sunday, 05'th Jun 2022
Investors should be able to count on recurring income with these stocks.
3 High-Yielding Dividend Stocks That Are Trading Below Their Book Values
11:07am, Wednesday, 01'st Jun 2022
These stocks are incredibly cheap, and aren't as risky as their low multiples suggest they might be.
Viatris to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
05:30pm, Friday, 20'th May 2022
PITTSBURGH , May 20, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today announced the company will participate in the Goldman Sachs 43rd Annual Global Healthc
2 Stocks That Are Ridiculously Cheap Right Now
07:52am, Saturday, 14'th May 2022
They present very different kinds of bargains.
3 Dirt-Cheap Stocks You Can Buy Right Now
07:04am, Saturday, 14'th May 2022
These stocks are inexpensive yet have solid underlying businesses.
Viatris Inc.'s (VTRS) CEO Michael Goettler on Q1 2022 Results - Earnings Call Transcript
01:58pm, Monday, 09'th May 2022
Viatris Inc. (NASDAQ:VTRS ) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Bill Szablewsk - Head, Global Capital Markets Michael Goettler - Chief Executive Officer Rajiv
Viatris Posts Q1 Profit Despite 5% Dip In Sales, Reiterates FY22 Guidance Above Consensus
01:51pm, Monday, 09'th May 2022
Viatris Inc (NASDAQ: VTRS) reported Q1 FY22 sales of $4.18 billion, down 5% Y/Y (-1% on an operational basis), below the consensus of $4.23 billion. Brands performed better than expectations, such a
Viatris' (VTRS) Q1 Earnings Beat, Revenues Miss Estimates
12:47pm, Monday, 09'th May 2022
Viatris (VTRS) beats on Q1 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.
Why Viatris Stock Is Popping Today
11:55am, Monday, 09'th May 2022
The drugmaker handily beat Wall Street earnings expectations in the first quarter.
Viatris (VTRS) Q1 Earnings Beat Estimates
09:51am, Monday, 09'th May 2022
Viatris (VTRS) delivered earnings and revenue surprises of 14.81% and 0.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Viatris: A Cigar Butt With Many Puffs Left
09:42am, Monday, 09'th May 2022
By selling its only growth asset, Viatris has turned out to be a cigar butt investment that still has many puffs left in it due to its strong free cash flow. Debt remains a concern, but the company co
Earnings Preview: Viatris (VTRS) Q1 Earnings Expected to Decline
04:33pm, Monday, 02'nd May 2022
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want Extra Income Every Month? Invest in These 3 High-Yielding Dividend Stocks
11:30am, Thursday, 28'th Apr 2022
Boost your portfolio's balance with these solid, income-generating investments.
